AU2002221651B2 - Pyrazole derivatives for the treatment of viral diseases - Google Patents

Pyrazole derivatives for the treatment of viral diseases Download PDF

Info

Publication number
AU2002221651B2
AU2002221651B2 AU2002221651A AU2002221651A AU2002221651B2 AU 2002221651 B2 AU2002221651 B2 AU 2002221651B2 AU 2002221651 A AU2002221651 A AU 2002221651A AU 2002221651 A AU2002221651 A AU 2002221651A AU 2002221651 B2 AU2002221651 B2 AU 2002221651B2
Authority
AU
Australia
Prior art keywords
alkyl
substituted
methyl
substituents
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002221651A
Other languages
English (en)
Other versions
AU2002221651A1 (en
Inventor
Brian William Dymock
Philip Stephen Jones
John Herbert Merrett
Martin John Parratt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2002221651A1 publication Critical patent/AU2002221651A1/en
Application granted granted Critical
Publication of AU2002221651B2 publication Critical patent/AU2002221651B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2002221651A 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases Ceased AU2002221651B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0024795.7 2000-10-10
GBGB0024795.7A GB0024795D0 (en) 2000-10-10 2000-10-10 Pyrazole derivatives for the treatment of viral diseases
PCT/EP2001/011474 WO2002030907A1 (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases

Publications (2)

Publication Number Publication Date
AU2002221651A1 AU2002221651A1 (en) 2002-06-27
AU2002221651B2 true AU2002221651B2 (en) 2006-10-19

Family

ID=9900999

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002221651A Ceased AU2002221651B2 (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
AU2165102A Pending AU2165102A (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2165102A Pending AU2165102A (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases

Country Status (28)

Country Link
US (2) US6699887B2 (enExample)
EP (1) EP1326843A1 (enExample)
JP (1) JP4015548B2 (enExample)
KR (1) KR100534158B1 (enExample)
CN (2) CN1680333A (enExample)
AR (1) AR030858A1 (enExample)
AU (2) AU2002221651B2 (enExample)
BR (1) BR0114483A (enExample)
CA (1) CA2423515A1 (enExample)
CZ (1) CZ20031297A3 (enExample)
EC (1) ECSP034547A (enExample)
GB (1) GB0024795D0 (enExample)
GT (1) GT200100201A (enExample)
HR (1) HRP20030251A2 (enExample)
HU (1) HUP0302722A2 (enExample)
IL (1) IL154875A0 (enExample)
MA (1) MA26951A1 (enExample)
MX (1) MXPA03003070A (enExample)
NO (1) NO20031615L (enExample)
NZ (1) NZ524740A (enExample)
PA (1) PA8530301A1 (enExample)
PE (1) PE20020750A1 (enExample)
PL (1) PL362918A1 (enExample)
RU (1) RU2270832C2 (enExample)
UY (1) UY26956A1 (enExample)
WO (1) WO2002030907A1 (enExample)
YU (1) YU27203A (enExample)
ZA (1) ZA200302519B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002325221B2 (en) * 2001-06-04 2008-07-31 F. Hoffmann-La Roche Ag Pyrazole Derivatives as HIV Reverse Transcriptase Inhibitors

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083005A1 (en) * 2000-09-29 2009-07-29 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
US7230025B2 (en) 2002-09-26 2007-06-12 Pfizer, Inc. Pyrazole derivatives
EP1546132A1 (en) * 2002-09-26 2005-06-29 Pfizer Limited Pyrazole derivatives as reverse transcriptase inhibitors
DE60319254T2 (de) 2002-09-26 2009-02-12 Pfizer Inc. Pyrazolamide zur behandlung von hiv-infektionen
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
GB0223234D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
GB0223232D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
CA2518823A1 (en) * 2003-03-24 2004-10-07 F.Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
CA2569530C (en) * 2004-07-01 2013-07-30 Daiichi Asubio Pharma Co.,Ltd. Thienopyrazole derivative having pde 7 inhibitory activity
US20070005049A1 (en) * 2005-06-30 2007-01-04 Comben Richard H Apparatus and Method of Treating Urinary Incontinence by Heating Urethra
AU2007270814B2 (en) * 2006-07-05 2011-07-14 Pfizer Products Inc. Pyrazole derivatives as cytochrome P450 inhibitors
PL2057125T3 (pl) * 2006-08-16 2011-09-30 Hoffmann La Roche Nienukleozydowe inhibitory odwrotnej transkryptazy
GB0713479D0 (en) * 2007-07-11 2007-08-22 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
RU2495878C2 (ru) 2007-12-21 2013-10-20 Ф.Хоффманн-Ля Рош Аг Гетероциклические антивирусные соединения
GB0823000D0 (en) * 2008-12-17 2009-01-28 Syngenta Participations Ag Isothiazole and pyrazole derivatives with plant growth regulating properties
NZ595233A (en) 2009-02-25 2013-01-25 Daiichi Sankyo Co Ltd Tricyclic pyrazolopyrimidine derivatives
FR2951549B1 (fr) 2009-10-15 2013-08-23 Olivier Schussler Procede d'obtention de bioprotheses medicales implantables
EP2610260A4 (en) 2010-08-23 2014-01-15 Daiichi Sankyo Co Ltd CRYSTAL OF TRICYCLIC PYRAZOLPYRIMIDINE DERIVATIVE
WO2012026433A1 (ja) 2010-08-23 2012-03-01 第一三共株式会社 三環性ピラゾロピリミジン誘導体のフリー体結晶
WO2014074628A1 (en) * 2012-11-08 2014-05-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compounds for treating hiv and methods for using the compounds
US9925190B2 (en) 2015-02-16 2018-03-27 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting HIV-1 Nef
EP3778583B1 (en) 2018-03-30 2025-06-18 Sumitomo Chemical Company, Limited Heterocyclic compound and arthropod pest control composition containing same
WO2020081856A1 (en) * 2018-10-18 2020-04-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibitors of hiv-1 nef for the treatment of hiv disease
FR3121927B1 (fr) 2021-04-19 2023-03-31 Eiffage Genie Civil Terrassement Procédé d’inertage des boues d’excavation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627423A1 (en) * 1992-01-22 1994-12-07 Nissan Chemical Industries, Limited Substituted pyrazole derivative and agrohorticultural bactericide
US6005109A (en) * 1997-10-30 1999-12-21 Pflizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9307664A (pt) * 1992-12-17 1999-06-29 Pfizer Pirazóis substituídos como antagonistas
WO1994013643A1 (en) * 1992-12-17 1994-06-23 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having crf antagonist activity
TW336932B (en) * 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
WO2006027423A1 (fr) * 2004-08-09 2006-03-16 Simag Developpement Dispositif de saisie comportant un capteur optique suivi d’un moyen de filtrage

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627423A1 (en) * 1992-01-22 1994-12-07 Nissan Chemical Industries, Limited Substituted pyrazole derivative and agrohorticultural bactericide
US6005109A (en) * 1997-10-30 1999-12-21 Pflizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002325221B2 (en) * 2001-06-04 2008-07-31 F. Hoffmann-La Roche Ag Pyrazole Derivatives as HIV Reverse Transcriptase Inhibitors

Also Published As

Publication number Publication date
CA2423515A1 (en) 2002-04-18
YU27203A (sh) 2006-05-25
CN1469865A (zh) 2004-01-21
ECSP034547A (es) 2003-05-26
CN1191239C (zh) 2005-03-02
GT200100201A (es) 2002-05-23
PL362918A1 (en) 2004-11-02
IL154875A0 (en) 2003-10-31
WO2002030907A1 (en) 2002-04-18
AU2165102A (en) 2002-04-22
MA26951A1 (fr) 2004-12-20
ZA200302519B (en) 2004-06-30
KR100534158B1 (ko) 2005-12-06
UY26956A1 (es) 2002-04-26
HK1061021A1 (en) 2004-09-03
JP2004511469A (ja) 2004-04-15
AR030858A1 (es) 2003-09-03
US6699887B2 (en) 2004-03-02
NO20031615D0 (no) 2003-04-09
CZ20031297A3 (cs) 2004-01-14
GB0024795D0 (en) 2000-11-22
HRP20030251A2 (en) 2005-02-28
BR0114483A (pt) 2003-07-01
US20040192752A1 (en) 2004-09-30
US20030018197A1 (en) 2003-01-23
RU2270832C2 (ru) 2006-02-27
JP4015548B2 (ja) 2007-11-28
MXPA03003070A (es) 2003-07-14
NO20031615L (no) 2003-05-23
PA8530301A1 (es) 2002-07-30
PE20020750A1 (es) 2002-08-21
HUP0302722A2 (hu) 2003-12-29
RU2003112610A (ru) 2005-02-20
EP1326843A1 (en) 2003-07-16
KR20030046492A (ko) 2003-06-12
US7183296B2 (en) 2007-02-27
CN1680333A (zh) 2005-10-12
NZ524740A (en) 2005-09-30

Similar Documents

Publication Publication Date Title
AU2002221651B2 (en) Pyrazole derivatives for the treatment of viral diseases
AU2002221651A1 (en) Pyrazole derivatives for the treatment of viral diseases
JP7519464B2 (ja) ヘテロ芳香族大環状エーテル化学療法剤
JP4990783B2 (ja) ２−ヘテロアリール置換インドール誘導体
AU755498B2 (en) 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
JP6081582B2 (ja) Ｗｎｔシグナリング阻害剤、組成物およびその用途としての化合物
CN105764514B (zh) 作为tam族激酶抑制剂的氨基吡啶衍生物
JP2024138377A (ja) ヘテロ芳香族大環状エーテル化学療法剤
AU2021209744B2 (en) Novel heterocyclic compounds useful as Aurora A selective inhibitors
AU2008242720A1 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
IL197664A (en) Biaryl urea compounds, medicinal preparations containing them and their use in the preparation of drugs for treatment
JP2010502615A (ja) ５−リポキシゲナーゼ活性化タンパク質（ｆｌａｐ）の阻害剤
PT885212E (pt) Quinoxalinodionas
JP2025505830A (ja) Ｒａｄ５１阻害剤としての新規二環式化合物
CN115916196A (zh) 杂芳族大环醚化学治疗剂
JP2017095498A (ja) Ｗｎｔシグナリング阻害剤、組成物およびその用途としての化合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired